Oxford Nanopore Technologies PLC on Thursday touted the progress of a research group in Australia that has just received genomic funding for a project using Oxford Nanopore sequencing technology.

The Oxford, England-based company, which develops and sells nanopore sequencing products, said its technology will be used by Ira Deveson in a three-year project at the Garvan Institute of Medical Research.

Deveson, whose doctorate focused on genome or transcriptome research and bioinfomatics, is trying to establish a national sequencing programme to make it easier to identify the genetic causes of rare diseases.

According to Oxford Nanopore, researchers involved in the project aim to raise future diagnostic rates by incorporating long nanopore sequencing reads into rare genetic disease characterisation.

The firm didn’t say how much funding has been granted.

‘We are delighted for the team and congratulate the researchers on being awarded this important funding. It is great to see so much research being dedicated to rare genetic disorders and with nanopore sequencing data they will get much more comprehensive insights,’ said Chief Executive Officer Gordon Sanghera.

‘What you’re missing matters, so with Oxford Nanopore’s ability to sequence any-length fragments of DNA we believe the team will be able to resolve significant blind spots and we look forward to hearing about their progress and discoveries.’

Oxford Nanopore shares were trading 1.2% lower at 190.90 pence each in London on Thursday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.